Regular Article CLINICAL TRIALS AND OBSERVATIONS Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R
نویسندگان
چکیده
Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R Matteo G. Della Porta, Emilio Paolo Alessandrino, Andrea Bacigalupo, Maria Teresa van Lint, Luca Malcovati, Cristiana Pascutto, Michele Falda, Massimo Bernardi, Francesco Onida, Stefano Guidi, Anna Paola Iori, Raffaella Cerretti, Paola Marenco, Pietro Pioltelli, Emanuele Angelucci, Rosi Oneto, Francesco Ripamonti, Paolo Bernasconi, Alberto Bosi, Mario Cazzola, and Alessandro Rambaldi, on behalf of Gruppo Italiano Trapianto di Midollo Osseo
منابع مشابه
CLINICAL TRIALS AND OBSERVATIONS Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS
Clonal cytogenetic abnormalities are a major risk factor for relapse after hematopoietic cell transplantation (HCT) for myelodysplastic syndrome (MDS). We determined the impact of the recently established 5-group cytogenetic classification of MDS on outcome after HCT. Results were compared with the impact of the International Prognostic Scoring System (IPSS) 3 cytogenetic risk groups, and the a...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Allogeneic hematopoietic cell transplantation after conditioning with 131I–anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome
We conducted a study to estimate the maximum tolerated dose (MTD) of 131I– anti-CD45 antibody (Ab; BC8) that can be combined with a standard reduced-intensity conditioning regimen before allogeneic hematopoietic cell transplantation. Fiftyeight patients older than 50 years with advanced acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) were treated with 131I-BC8 Ab and fl...
متن کاملRegular Article CLINICAL TRIALS AND OBSERVATIONS Outcome of patients with abnl(17p) acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation
Hochschule Hannover, Klinik für Hämatologie, Hämostaseologie, Onkologie und Stammzelltransplantation, Hannover, Germany; Department of Hematology, Hospital Universitario La Fe, Valencia University Medical School, Valencia, Spain; Stiftung Deutsche Klinik für Diagnostik GmbH, Zentrum für Blutstammzellund Knochenmarktransplantation, Wiesbaden, Germany; Klinikum der Johann Wolfgang Goethe Universi...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma
Bortezomib, a potent and reversible proteasome inhibitor, affects the myeloma cell and its microenvironment, resulting in downregulation of growth and survival signaling pathways and durable responses in patients with relapsed and refractory myeloma. Potential associations between baseline parameters and outcomes with bortezomib were explored in 202 patients who received bortezomib 1.3 mg/m2 tw...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Evidence for reduced B-cell progenitors in early (low-risk) myelodysplastic syndrome
Early, low-risk International Prognostic Scoring System (IPSS) myelodysplastic syndrome (MDS) is a heterogeneous disorder where the molecular and cellular hematopoietic defects are poorly understood. To gain insight into this condition, we analyzed gene expression profiles of marrow CD34 progenitor cells from normal-karyotype, low-blast-count MDS patients, age-matched controls, and patients wit...
متن کامل